Eli Lilly (NYSE: LLY) shares closed at $1,216.55 on July 9, 2026, just shy of their all-time high, pushing the company's market capitalization to roughly $1.09 trillion. The stock's four-digit price tag has sparked discussions of a potential stock split, but the real story for investors lies in the company's evolving pricing strategy for its blockbuster obesity drugs.
Revenue Growth Amid Pricing Pressure
In the first quarter of 2026, Lilly reported a 56% year-over-year surge in total revenue to $19.8 billion. However, this impressive top-line growth was tempered by a 13% headwind from lower realized net prices, which reflect the actual amount Lilly pockets after rebates and discounts. Volume growth of 65% more than offset the pricing drag, underscoring the company's strategy of trading lower prices for higher unit sales.
Medicare GLP-1 Bridge Program
Starting July 1, 2026, a new Medicare GLP-1 Bridge program provides eligible Part D beneficiaries access to select weight-loss medications for $50 per month through December 31, 2027. Lilly's offerings under this program include its injectable Zepbound and its recently launched oral obesity drug, Foundayo. The company estimates that approximately 20 million Medicare patients could qualify for obesity drugs based on clinical criteria, according to Ilya Yuffa, president of Eli Lilly USA.
Foundayo: A Game-Changer?
Foundayo, a once-daily oral pill, differentiates itself by not requiring patients to consider food or water intake, a convenience that some rival products lack. CEO David Ricks has stated that this accessibility could "level the playing field" for patients deterred by stigma or complex treatment regimens. Early prescription data showed 7,335 scripts in the first four weeks, a slower start compared to Novo Nordisk's Wegovy pill. However, RBC Capital analyst Trung Huynh noted that investors are looking past initial weekly metrics, emphasizing that Foundayo would need approximately 22,000 weekly scripts to meet consensus estimates for second-quarter sales.
Novo Nordisk's Competitive Response
Novo Nordisk (NYSE: NVO) has similarly expanded access, offering its Wegovy injection and pill at $50 per month for eligible Medicare patients. The company reported over 3 million prescriptions for the Wegovy pill since its January launch, highlighting the intense competition in the obesity drug market. Viking Therapeutics (NASDAQ: VKTX), a smaller player, is developing its oral VK2735 for obesity and other metabolic diseases, adding to the pipeline rivalry.
Analyst Sentiment and Valuation
Despite the pricing challenges, analyst sentiment remains bullish. The average price target from analysts polled by StockAnalysis using S&P Global data stands at $1,240, just above current trading levels. RBC Capital recently raised its target to $1,500, while J.P. Morgan increased its to $1,400. The key question for investors is whether the $50 access program, combined with simpler dosing and expanded supply, can sustain volume growth. If volume growth decelerates, defending the trillion-dollar valuation premium may become more difficult.
Market Context
Lilly's obesity drug portfolio, including Mounjaro (diabetes), Zepbound (obesity), and Foundayo (oral), continues to drive strong performance. Mounjaro revenue rose 125% to $8.662 billion in Q1, while Zepbound grew 80% to $4.160 billion. The company's late-stage candidate retatrutide also remains in development. With a market cap near $1.09 trillion, Lilly's valuation reflects high expectations for continued growth in the obesity drug market.
